Akari Therapeutics, Plc (NASDAQ:AKTX) Short Interest Update

Akari Therapeutics, Plc (NASDAQ:AKTX) was the target of a significant growth in short interest in the month of October. As of October 31st, there was short interest totalling 21,300 shares, a growth of 15.1% from the October 15th total of 18,500 shares. Based on an average trading volume of 16,500 shares, the days-to-cover ratio is presently 1.3 days. Approximately 0.2% of the shares of the company are short sold.

Akari Therapeutics Price Performance

Shares of AKTX opened at $2.08 on Friday. The stock has a 50 day simple moving average of $2.73 and a 200-day simple moving average of $2.85. Akari Therapeutics has a 1 year low of $1.08 and a 1 year high of $4.40.

Wall Street Analyst Weigh In

Separately, StockNews.com began coverage on shares of Akari Therapeutics in a report on Sunday, November 10th. They issued a “sell” rating for the company.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.